SURI actively manages a multi-asset strategy by investing in equity and fixed income securities of companies in the biotech, pharmaceuticals, healthcare technology, and life science tools and services industries. Investments include common and preferred stocks, convertible bonds, structured notes, corporate notes and bonds, and ETFs. There are no restrictions as to the currency, issuer capitalization, or country for equities, and debt credit quality, maturity, structure, or issuer type for debt securities. The management team identifies attractive investment opportunities by evaluating the scientific proposition of the issuer, the probability that the science will lead to a product or treatment, and projected profits from each successful product or treatment. The fund typically includes small- and mid-caps. SURI may invest up to 20% in derivatives to leverage exposure and partially hedge against market declines. It holds cash and cash-like instruments as collateral.